IP Verse

Schiener patent opposition analysis

The comprehensive analysis of Schiener opposition landscape, with a particular emphasis on intellectual property (IP) dynamics.

Latest patent oppositions filed by Schiener

Stay updated with the latest patent oppositions filed by Schiener

Patent NumberTitleApplicantOpposition DateOpposition Company
EP3351246
Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated AngiogenesisNOVARTISFeb 22, 2020TEVA PHARMACEUTICAL INDUSTRIES
EP2964202
Oral Formulations Of DeferasiroxNOVARTISJul 23, 2019TEVA PHARMACEUTICAL INDUSTRIES
EP2598119
Preservative Free Brimonidine And Timolol SolutionsALLERGANJun 18, 2019WCHTERSHUSER & HARTZ
EP2598118
Preservative Free Bimatoprost And Timolol SolutionsALLERGANJun 4, 2019WCHTERSHUSER & HARTZ
EP2490986
Methods And Systems For Purifying Non-Complexed Botulinum NeurotoxinREVANCE THERAPEUTICSMay 2, 2019WCHTERSHUSER & HARTZ
EP1983984
Tuberous Sclerosis TreatmentNOVARTISDec 7, 2018TEVA PHARMACEUTICAL INDUSTRIES
EP3124018
Oral Formulations Of DeferasiroxNOVARTISSep 20, 2018TEVA PHARMACEUTICAL INDUSTRIES
EP2578228
Non-Diffusive Botulinum Toxin Causing Local Muscle Paralysis, And Purification Method ThereofMEDEXGENAug 14, 2018WCHTERSHUSER & HARTZ
EP2269603
Treatment Of Solid Tumours With Rapamycin DerivativesNOVARTISFeb 22, 2016ACTAVIS PTC EHF
EP2269603
Treatment Of Solid Tumours With Rapamycin DerivativesNOVARTISFeb 18, 2016TEVA PHARMACEUTICALS

Top clients of Schiener

Top companies who are the clients of Schiener

CompanyTotal
TEVA PHARMACEUTICAL INDUSTRIES4
WCHTERSHUSER & HARTZ4
WACHTERSHAUSER & HARTZ PATENTANWALTSPARTNERSCHAFT MBB2
WACHTERSHAUSER & HARTZ PATENTANWALTSPARTNERSCHAFT MBB BLODIG2
ACTAVIS PTC EHF1
TEVA PHARMACEUTICALS1